Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 326-330

  Ooi, Esther M M ^a   Watts, Gerald F ^a   Chan, Dick C ^a   Nielsen, Lars B ^b   Plomgaard, Peter ^b   Dahlbäck, Bjorn ^c   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

ApoM; Kinetics; Metabolic syndrome; Obesity

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN M; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME KINETICS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; OBESITY; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEINS; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; TRIGLYCERIDES;

EID: 77952420904     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.11.024     Document Type: Article

References (29)

1. van der Steeg W.A., Holme I., Boekholdt S.M., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008, 51:634-642.
2. Tailleux A., Duriez P., Fruchart J.C., Clavey V. Apolipoprotein A-II. HDL metabolism and atherosclerosis. Atherosclerosis 2002, 164:1-13.
3. Nielsen L.B., Christoffersen C., Ahnstrom J., Dahlback B. ApoM: gene regulation and effects on HDL metabolism. Trends Endocrinol Metab 2009, 20:66-71.
4. Christoffersen C., Nielsen L.B., Axler O., Andersson A., Johnsen A.H., Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47:1833-1843.
5. Wolfrum C., Poy M.N., Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005, 11:418-422.
6. Wolfrum C., Howell J.J., Ndungo E., Stoffel M. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem 2008, 283:16940-16949.
7. Christoffersen C., Jauhiainen M., Moser M., et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008, 283:1839-1847.
8. Mulya A., Seo J., Brown A.L., et al. Apolipoprotein M expression increases the size of nascent pre-beta HDL formed by ATP binding cassette transporter A1 (ABCA1). J Lipid Res 2009, 10.1194/jlr.M002162.
9. Huang X.S., Zhao S.P., Hu M., Luo Y.P. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med Hypotheses 2007, 69:136-140.
10. Ahnstrom J., Axler O., Jauhiainen M., et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res 2008, 49:1912-1917.
11. Dullaart R.P., Plomgaard P., de Vries R., Dahlback B., Nielsen L.B. Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. Clin Chim Acta 2009, 406:129-133.
12. Plomgaard P., Dullaart R.P., de Vries R., Groen A.K., Dahlback B., Nielsen L.B. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med 2009.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
14. Watts G.F., Barrett P.H., Ji Juying, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803-811.
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990, 31:545-548.
17. Cohn J.S., Wagner D.A., Cohn S.D., Millar J.S., Schaefer E.J. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990, 85:804-811.
18. Frenais R., Ouguerram K., Maugeais C., et al. Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res 1999, 40:1506-1511.
19. Ooi E.M., Watts G.F., Farvid M.S., et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res 2005, 13:1008-1016.
20. Velez-Carrasco W., Lichtenstein A.H., Barrett P.H., et al. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins. J Lipid Res 1999, 40:1695-1700.
21. Riches F.M., Watts G.F., Naoumova R.P., Kelly J.M., Croft K.D., Thompson G.R. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998, 22:414-423.
22. Su W., Jiao G., Yang C., Ye Y. Evaluation of apolipoprotein M as a biomarker of coronary artery disease. Clin Biochem 2009, 42:365-370.
23. Ahnstrom J., Faber K., Axler O., Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res 2007, 48:1754-1762.
24. Duan J., Dahlback B., Villoutreix B.O. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001, 499:127-132.
25. Chan D.C., Barrett P.H., Ooi E.M., Ji J., Chan D.T., Watts G.F. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab 2009, 94:989-997.
26. Rashid S., Watanabe T., Sakaue T., Lewis G.F. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-429.
27. Lamarche B., Rashid S., Lewis G.F. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 1999, 286:145-161.
28. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
29. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.